Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.70 |
| ▸ | CA2 | P00918 | 4/20 | 0.70 |
| ▸ | CA7 | P43166 | 3/20 | 0.70 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.70 |
| ▸ | CA1 | P00915 | 4/20 | 0.67 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14798746 | 0.84 | CA2 (0.49) | CA12CA2CA7CA14CA1 | |
| SCHEMBL3194925 | 0.84 | SMN1; SMN2 (0.54) | CA12CA2CA7CA14CA1 | |
| Benzyl(Benzylsulfamoyl)Amine SCHEMBL2298224 | 0.83 | CA12 (1.00) | CA12CA2CA7CA14CA1 | |
| SCHEMBL12002489 | 0.83 | CA2 (0.49) | CA12CA2CA7CA14CA1 | |
| SCHEMBL30136175 | 0.82 | CA12 (0.68) | CA12CA2CA7CA14CA1 | |
| SCHEMBL3209241 | 0.81 | CA12 (0.60) | CA12CA7CA14LMNAKMT2A | |
| SCHEMBL3211224 | 0.80 | HTT (0.69) | CA12CA7CA14CA1LMNA | |
| SCHEMBL6337412 | 0.77 | CA12 (1.00) | CA12CA2CA7CA14CA1 | |
| SCHEMBL3195623 | 0.76 | L3MBTL1 (0.56) | KMT2AATML3MBTL1MEN1KDM4E | |
| SCHEMBL1134868 | 0.76 | CA2 (0.76) | CA12CA2CA7CA14CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0874809-B1 | CARBAMOYLOXY DERIVATIVES OF MUTILINE AND THEIR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2003-08-27 | — | — | EP | claimed |
| US-6239175-B1 | Carbamoyloxy derivatives of mutiline and their use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-29 | — | — | US | claimed |
| US-11850286-B2 | Sulfamide linker, conjugates thereof, and methods of preparation | SYNAFFIX B.V. (NL) | 2023-12-26 | — | — | US | disclosed |
| US-20210030886-A1 | SULFAMIDE LINKER, CONJUGATES THEREOF, AND METHODS OF PREPARATION | SYNAFFIX B.V. (NL) | 2021-02-04 | — | — | US | disclosed |
| US-10792369-B2 | Sulfamide linker, conjugates thereof, and methods of preparation | SYNAFFIX B.V. (NL) | 2020-10-06 | — | — | US | disclosed |
| US-20170298145-A1 | SULFAMIDE LINKER, CONJUGATES THEREOF, AND METHODS OF PREPARATION | SYNAFFIX B.V. (NL) | 2017-10-19 | — | — | US | disclosed |
| US-9636421-B2 | Sulfamide linker, conjugates thereof, and methods of preparation | SYNAFFIX B.V. (NL) | 2017-05-02 | — | — | US | disclosed |
| EP-0874809-B1 | CARBAMOYLOXY DERIVATIVES OF MUTILINE AND THEIR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2003-08-27 | — | — | EP | disclosed |
| US-6239175-B1 | Carbamoyloxy derivatives of mutiline and their use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-29 | — | — | US | disclosed |
| US-6020368-A | MICROBIOCIDES | HINKS JEREMY DAVID (US) | 2000-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298145-A1 | SULFAMIDE LINKER, CONJUGATES THEREOF, AND METHODS OF PREPARATION | SULT1E1, SULT1A1, SULT2A1 | CA12 654/4885CA2 1487/4885CA7 1918/4885 |
| US-10792369-B2 | Sulfamide linker, conjugates thereof, and methods of preparation | SULT1E1, SULT1A1, SULT2A1 | CA12 654/4885CA2 1487/4885CA7 1918/4885 |
| US-11850286-B2 | Sulfamide linker, conjugates thereof, and methods of preparation | SULT1E1, SULT1A1, SULT2A1 | CA12 654/4885CA2 1487/4885CA7 1918/4885 |
| US-20210030886-A1 | SULFAMIDE LINKER, CONJUGATES THEREOF, AND METHODS OF PREPARATION | SULT1E1, SULT1A1, SULT2A1 | CA12 654/4885CA2 1487/4885CA7 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.